<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229382</url>
  </required_header>
  <id_info>
    <org_study_id>ML29157</org_study_id>
    <secondary_id>2015-005439-41</secondary_id>
    <nct_id>NCT03229382</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell</brief_title>
  <acronym>OPERAPLRG-10</acronym>
  <official_title>Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is the evaluation of efficacy and safety of obinutuzumab&#xD;
      preemptive treatment at the time of the molecular relapse after first line immunochemotherapy&#xD;
      with autologous stem cell transplantation in mantle cell lymphoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD negativity defined as a MRD level</measure>
    <time_frame>2 months after obinutuzumab treatment</time_frame>
    <description>Molecular response rate (molRR) defined as a rate of molecular response with at least 10-4 sensitivity level assessed by quantitative RQ-PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>defined as the time from the date of the first obinutuzumab infusion to disease progression or relapse, as determined by the investigator using the Lugano Classification or death from any cause after the last dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to molecular relapse</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>as the time from the date of the first obinutuzumab infusion to the first occurrence of molecular disease relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>defined as the time from the date of the initiation of the first line treatment to the death from any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse/progression</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse, as determined by the investigator using the Lugano Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>defined as the time from the date of the first obinutuzumab infusion to the first evidence of disease progression or relapse (as determined by the investigator using the Lugano Classification), death from any reason, start of the another anti-lymphoma treatment, SAE preventing continuation of the protocol treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status measured with EQ-5D from EuroQoL Group</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>with EQ-5D from EuroQoL Group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerability assessment</measure>
    <time_frame>3 years and 2 month</time_frame>
    <description>reporting of serious adverse events (SAEs), adverse events (AEs) and adverse events of special interest</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.</description>
    <arm_group_label>Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22</arm_group_label>
    <other_name>Gazyvaro</other_name>
    <other_name>GA101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with evidence of MCL molecular relapse in peripheral blood or/and bone&#xD;
             marrow,&#xD;
&#xD;
          -  Diagnosis of mantle cell lymphoma confirmed by histopathology&#xD;
&#xD;
          -  Presence of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or&#xD;
             BCL1-IGH fusion gene as a molecular marker used for minimal residual disease (MRD)&#xD;
             assessment,&#xD;
&#xD;
          -  Patients in CR/PR after first-line treatment with myeloablative consolidation and&#xD;
             ASCT,&#xD;
&#xD;
          -  Patients without evidence of mantle cell lymphoma progression/relapse according to the&#xD;
             Lugano Classification criteria (2014),&#xD;
&#xD;
          -  ECOG performance status ≤ 2,&#xD;
&#xD;
          -  Signed patient's informed consent form,&#xD;
&#xD;
          -  Survival prognosis &gt; 6 months,&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test result prior to&#xD;
             initiation of treatment with the study medication and must consent to undergo&#xD;
             pregnancy tests during the treatment period.,&#xD;
&#xD;
          -  Women of child-bearing potential must consent either to sexual abstinence or to using&#xD;
             effective contraception (that results in a failure rate of &lt; 1% per year) while&#xD;
             receiving the study medication and for 18 months after its discontinuation,&#xD;
&#xD;
          -  Men must consent either to using an acceptable contraception method (that results in a&#xD;
             failure rate of &lt; 1% per year) or continued sexual abstinence while receiving the&#xD;
             study medication and for 6 months after its discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system involvement,&#xD;
&#xD;
          -  Chemotherapy, radiation therapy or any other antineoplastic treatment (including&#xD;
             steroids, monoclonal antibodies or medications at the stage of clinical studies,&#xD;
             before receiving marketing authorisation) after ASCT and before administration of the&#xD;
             study medication,&#xD;
&#xD;
          -  Major surgery within 28 days prior to the study treatment initiation,&#xD;
&#xD;
          -  Renal impairment (plasma creatinine concentration &gt; 1.5 × upper limit of normal and/or&#xD;
             creatinine clearance ≤ 40 ml/h),&#xD;
&#xD;
          -  Hepatic impairment (total bilirubin concentration &gt; 1.5 × upper limit of normal, AST&#xD;
             and ALT &gt; 2.5 × upper limit of normal),&#xD;
&#xD;
          -  Hb&lt; 9 g/dl, ANC &lt; 1.5 G/l, platelets &lt; 75 G/l,&#xD;
&#xD;
          -  International normalized ratio (INR) &gt; 1.5,&#xD;
&#xD;
          -  Clinically significant heart disease, including uncontrolled arrhythmias, unstable&#xD;
             coronary artery disease, serious congestive circulatory failure (NYHA III-IV),&#xD;
             myocardial infarction within 6 months before enrolment,&#xD;
&#xD;
          -  Other comorbidities, not responding to treatment, including, but not limited to:&#xD;
             hematopoietic system diseases, gastrointestinal system diseases, endocrine system&#xD;
             diseases, respiratory system diseases, neurological diseases, cerebral diseases and&#xD;
             mental diseases that could affect compliance with the protocol or interpretation of&#xD;
             results,&#xD;
&#xD;
          -  Active infections (viral, bacterial, fungal),&#xD;
&#xD;
          -  Coexistence of another neoplasm or a history of neoplastic disease (except for&#xD;
             adequately treated basal cell carcinoma or squamous cell skin carcinoma, in situ&#xD;
             cervical cancer or other neoplasm if the patient is in complete remission after at&#xD;
             least 5 years of treatment discontinuation),&#xD;
&#xD;
          -  Active HIV, HBV or HCV infection,&#xD;
&#xD;
          -  Positive test results for chronic hepatitis B. All patients must be tested for both&#xD;
             HBsAg and HBcAb at screening, if either of the tests is positive, the patient is not&#xD;
             eligible for inclusion in the trial. Patients who have protective titers of HBsAb&#xD;
             after vaccination are eligible provided they are negative for both HBsAg and HBcAb,&#xD;
&#xD;
          -  Positive testing for hepatitis C (hepatitis C virus [HCV] antibody serology testing).&#xD;
             Patients positive for HCV antibody are eligible only if polymerase chain reaction is&#xD;
             negative for HCV RNA,&#xD;
&#xD;
          -  Vaccination with live vaccines within 28 days prior to start of the preemptive&#xD;
             treatment,&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the study medication,&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michał Szymczyk, MD</last_name>
    <phone>+48 22-546-2448</phone>
    <email>michal.szymczyk@coi.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej- Curie Klinika Nowotworów Układu Chłonnego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michał Szymczyk, MD</last_name>
      <phone>+48 22-546-3248</phone>
      <email>michal.szymczyk@coi.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytetu Medycznego</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Wróbel, MD, PhD, Prof</last_name>
      <phone>+48 71-784-2576</phone>
      <email>tomasz.wrobel@umed.wroc.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCL, obinutuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

